Prostate Cancer Blog - malecare.org

CapSure Showed the Association of Statin and Nonsteroidal Anti-inflammatory Drug use with Prostate Cancer All Cause Survival

In the prostate cancer world we often discuss treatment options, some approved by the FDA and some not approved. Among the treatment options bantered about are statins (3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor) and nonsteroidal anti-inflammatory drugs (NSAIDs). According to the folklore both these drugs are associated with reducing the risk of prostate cancer and improved [...]

By Malecare|2012-11-19T15:09:47-05:00November 19th, 2012|Advanced Prostate Cancer, Drugs & Treatments, Uncategorized|0 Comments

Now an Early Access Site for Alpharedin Opens in New York

The Early Access Committee on which Malecare sits has been successful in adding an additional site in Long Island, New York to the Early Access Trial of Radium-233 Chloride (Alpharedin) for men with advanced prostate cancer who are castrate resistant and have at least two (2) bone metastases. If you are interested in this trial [...]

By Malecare|2012-11-18T10:50:10-05:00November 18th, 2012|Advanced Prostate Cancer, Alpharadin (radium-223), Clinical Trials, Clinical Trials, Drugs & Treatments, Early/Expanded Access Programs, Metastases, Uncategorized, Understanding APC|0 Comments

Xtandi Today & Tomorrow

Medivation, the pharmaceutical company that owns Xtandi (formerly known as MDV-3100), the new androgen receptor antagonist to treat castrate resistant advanced prostate cancer has a number of active clinical trials, despite the fact that it has already been approved for use. The current FDA approval is specific; it has been approved for men who are [...]

By Malecare|2017-10-19T10:50:30-04:00November 16th, 2012|Advanced Prostate Cancer, Drugs & Treatments, Enzalutamide (MDV-3100), MDV3100, Uncategorized, Understanding APC, Xtandi|1 Comment

Radium-223 (Alpharedin) Improves Survival in Men with Metastatic Prostate Cancer

At the October 28 meeting of the American Society for Radiation the final data from the ALSYMPCA trial were presented. The trial evaluated radium-223 (Alpharedin) in men with castrate-resistant prostate cancer that had spread to the bones. Alpharedin is part of a class of drugs called alpha-particle emitters that targets bone metastases. The good news [...]

By Malecare|2017-10-19T10:50:31-04:00November 15th, 2012|Advanced Prostate Cancer, Alpharadin (radium-223), Clinical Trials, Clinical Trials, Drugs & Treatments, Uncategorized, Understanding APC|2 Comments

So, Where Is Your Evidence – Is Our Propensity to Believe the Folk Law Wasting our Time & Money

Having hot flashes because of hormone deprivation therapy (ADT)? All of us dealing with advanced prostate cancer will be on ADT, it is the usual first line of therapy and it will continue until we die. Men who elect to have radiation to treat prostate cancer as their primary treatment modality will often have some [...]

By Malecare|2017-10-19T10:50:31-04:00November 13th, 2012|Advanced Prostate Cancer, Diet, Diet and Supplements, Drugs & Treatments, General Information, Hormone Therapy, Prostate Ponderings, Research, Uncategorized, Understanding APC|0 Comments